FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387249924> ?p ?o ?g. }

• W4387249924 endingPage "A31" @default.
• W4387249924 startingPage "A30" @default.
• W4387249924 abstract "SESSION TITLE: Asthma and Allergy SESSION TYPE: Original Investigations PRESENTED ON: 10/09/2023 08:30 am - 09:30 am PURPOSE: Neutrophilic asthma makes up to 50% of severe asthma cases, and therefore remains an area of great interest for directed therapies. Asthmatics have elevated levels of extracellular deoxyribonucleic acid (DNA) in sputum compared to healthy subjects. Nebulized recombinant human deoxyribonuclease (rhDNase, dornase alfa) randomly cleaves extracellular DNA released by airway neutrophils and other granulocytes, thereby reducing the viscosity of mucus. Benefits of dornase alfa are well-described in cystic fibrosis. Treatment with dornase alfa may be of benefit in stable neutrophilic asthma but has not been studied. In this pilot study, we studied neutrophilic asthmatics receiving 4 weeks of daily nebulized dornase alfa to assess safety profile of the study drug, as well as effect on lung function, symptom control (Asthma Control Test, ACT), and sputum characteristics and production. METHODS: This was an open label pilot study approved by our Institutional Review Board. We enrolled 19 adult asthma subjects (≥18 years). 4 subjects were ineligible due to screen failure after enrollment. The study design consisted of 3 visits. At Visit 1, participants underwent spirometry, ACT and sputum characteristic questionnaires, and sputum induction. Neutrophilic asthma was defined by sputum differential cell count of ≥40% neutrophils. Only those with defined sputum neutrophilia were enrolled in the therapeutic arm of the study. Neutrophilic asthmatics returned for Visits 2 and 3. At Visit 2, they received the first dose of nebulized dornase alfa. Nebulized dornase alfa was continued for total of 28-35 days. Participants returned for Visit 3 with repeat spirometry, ACT, sputum induction, and reported on sputum characteristics. RESULTS: A total of 15 subjects completed the study, 11 of whom were neutrophilic and 4 were non-neutrophilic. One neutrophilic subject was removed from analysis due to acute infection unrelated to the study. The study achieved its primary endpoint, which was assessing safety of the study drug. No subject withdrew from the study due to side effects from the study drug. There was not statistically significant improvement in lung function following 28 days of study drug. The median ACT improvement was 2 points (p=0.13). Sputum characteristic changes of neutrophilic asthmatics were notable with dornase alfa treatment. Ninety percent (9/10) noted it was easier to cough up sputum, and 80% (8/10) noted thinner mucus compared with baseline. CONCLUSIONS: This small pilot study of neutrophilic asthmatics showed safety in daily use of nebulized dornase alfa. A trend toward improved symptom control and notable improvement in ability to expectorate sputum due to thinner consistency was found with dornase alfa treatment. Further quantification of sputum characteristics was limited by a validated sputum questionnaire. CLINICAL IMPLICATIONS: Dornase alfa was associated with improved ability to expectorate and thickness of sputum in neutrophilic asthmatics in a stable state and may be a therapeutic option for these patients, but further study is needed. DISCLOSURES: Speaker/Speaker's Bureau relationship with Regeneron Please note: 04/11/22 - Current Added 04/15/2023 by Vamsi Guntur, source=Web Response, value=Honoraria Advisory Committee Member relationship with AstraZeneca Please note: 4/1/2021-Current Added 04/15/2023 by Vamsi Guntur, source=Web Response, value=Consulting fee Speaker/Speaker's Bureau relationship with AstraZeneca Please note: March 2023 - Current Added 04/15/2023 by Vamsi Guntur, source=Web Response, value=Nothing yet No relevant relationships by Christena Kolakowski Advisory Committee Member relationship with GSK Please note: 11/16/2021-11/7/2023 Added 03/27/2023 by Laurie Manka, source=Web Response, value=Honoraria Consultant relationship with IngenioRx Please note: 1/31/2022-Pres Added 03/27/2023 by Laurie Manka, source=Web Response, value=Consulting fee No relevant relationships by Richard Martin No relevant relationships by Camille Moore No relevant relationships by Allen Stevens" @default.
• W4387249924 created "2023-10-03" @default.
• W4387249924 creator A5033749081 @default.
• W4387249924 creator A5051212820 @default.
• W4387249924 creator A5052447524 @default.
• W4387249924 creator A5065861404 @default.
• W4387249924 creator A5078724703 @default.
• W4387249924 creator A5082854646 @default.
• W4387249924 date "2023-10-01" @default.
• W4387249924 modified "2023-10-03" @default.
• W4387249924 title "DORNASE ALFA IN STABLE NEUTROPHILIC ASTHMA" @default.
• W4387249924 doi "https://doi.org/10.1016/j.chest.2023.07.083" @default.
• W4387249924 hasPublicationYear "2023" @default.
• W4387249924 type Work @default.
• W4387249924 citedByCount "0" @default.
• W4387249924 crossrefType "journal-article" @default.
• W4387249924 hasAuthorship W4387249924A5033749081 @default.
• W4387249924 hasAuthorship W4387249924A5051212820 @default.
• W4387249924 hasAuthorship W4387249924A5052447524 @default.
• W4387249924 hasAuthorship W4387249924A5065861404 @default.
• W4387249924 hasAuthorship W4387249924A5078724703 @default.
• W4387249924 hasAuthorship W4387249924A5082854646 @default.
• W4387249924 hasBestOaLocation W43872499241 @default.
• W4387249924 hasConcept C126322002 @default.
• W4387249924 hasConcept C142724271 @default.
• W4387249924 hasConcept C2776042228 @default.
• W4387249924 hasConcept C2776301714 @default.
• W4387249924 hasConcept C2776938444 @default.
• W4387249924 hasConcept C2777802486 @default.
• W4387249924 hasConcept C2780333948 @default.
• W4387249924 hasConcept C2781069245 @default.
• W4387249924 hasConcept C71924100 @default.
• W4387249924 hasConcept C75603125 @default.
• W4387249924 hasConcept C90924648 @default.
• W4387249924 hasConceptScore W4387249924C126322002 @default.
• W4387249924 hasConceptScore W4387249924C142724271 @default.
• W4387249924 hasConceptScore W4387249924C2776042228 @default.
• W4387249924 hasConceptScore W4387249924C2776301714 @default.
• W4387249924 hasConceptScore W4387249924C2776938444 @default.
• W4387249924 hasConceptScore W4387249924C2777802486 @default.
• W4387249924 hasConceptScore W4387249924C2780333948 @default.
• W4387249924 hasConceptScore W4387249924C2781069245 @default.
• W4387249924 hasConceptScore W4387249924C71924100 @default.
• W4387249924 hasConceptScore W4387249924C75603125 @default.
• W4387249924 hasConceptScore W4387249924C90924648 @default.
• W4387249924 hasIssue "4" @default.
• W4387249924 hasLocation W43872499241 @default.
• W4387249924 hasOpenAccess W4387249924 @default.
• W4387249924 hasPrimaryLocation W43872499241 @default.
• W4387249924 hasRelatedWork W1527121584 @default.
• W4387249924 hasRelatedWork W2040773639 @default.
• W4387249924 hasRelatedWork W2099861526 @default.
• W4387249924 hasRelatedWork W2116970310 @default.
• W4387249924 hasRelatedWork W2165434242 @default.
• W4387249924 hasRelatedWork W2293317142 @default.
• W4387249924 hasRelatedWork W2375063122 @default.
• W4387249924 hasRelatedWork W2399767733 @default.
• W4387249924 hasRelatedWork W2921032955 @default.
• W4387249924 hasRelatedWork W1898595065 @default.
• W4387249924 hasVolume "164" @default.
• W4387249924 isParatext "false" @default.
• W4387249924 isRetracted "false" @default.
• W4387249924 workType "article" @default.